Macrocure nets $49.8mm through IPO
Executive Summary
Israeli wound therapy developer Macrocure Ltd. completed its initial public offering in the US, netting $49.8mm through the sale of 5.35mm ordinary shares at $10 (below its intended range of $13-15).
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice